💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Technetium Medronate

CHEMBL2110576 Phase 4 已批准 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
130.2 g/mol
LogP
2.5
Phase
4

Technetium medronate (99mTc-MDP, methylene diphosphonate) is the most widely used bone-scanning radiopharmaceutical, adsorbing to hydroxyapatite crystals in areas of increased osteoblastic activity and bone remodeling. It is used in whole-body bone scintigraphy for detection of bone metastases from cancers such as breast and bladder cancer, as well as for evaluation of osteomyelitis, fractures, and metabolic bone disease. The three-phase bone scan technique with this agent provides information on blood flow, blood pool, and delayed bone uptake.

分子量

130.1800 g/mol

LogP

2.50

TPSA

37.30 Ų

Lipinski 五规则

符合

治疗领域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Breast Cancer Prostate Cancer Colorectal Cancer

作用机制

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

SMILES

CCCCCCC(=O)O

InChI

InChI=1S/C7H14O2/c1-2-3-4-5-6-7(8)9/h2-6H2,1H3,(H,8,9)

Molecular Formula

C7H14O2

HBD / HBA

1 / 2

可旋转键数

5

重原子数

9

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

Technetium medronate (99mTc-MDP, methylene diphosphonate) is the most widely used bone-scanning radiopharmaceutical, adsorbing to hydroxyapatite crystals in areas of increased osteoblastic activity and bone remodeling. It is used in whole-body bone scintigraphy for detection of bone metastases from cancers such as breast and bladder cancer, as well as for evaluation of osteomyelitis, fractures, and metabolic bone disease. The three-phase bone scan technique with this agent provides information on blood flow, blood pool, and delayed bone uptake.

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Yes, Technetium Medronate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2110576. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 8094. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.